Impact of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Renal Function in Patient with Heart Failure.
chronic kidney disease
heart failure
kidney
Journal
Journal of cardiovascular development and disease
ISSN: 2308-3425
Titre abrégé: J Cardiovasc Dev Dis
Pays: Switzerland
ID NLM: 101651414
Informations de publication
Date de publication:
17 Dec 2021
17 Dec 2021
Historique:
received:
29
10
2021
revised:
30
11
2021
accepted:
14
12
2021
entrez:
23
12
2021
pubmed:
24
12
2021
medline:
24
12
2021
Statut:
epublish
Résumé
Hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor is a recently introduced oral agent to treat renal anemia, but its clinical implications on renal functioning in patients with heart failure remains unknown. We studied an 81-year-old man with heart failure with mildly reduced ejection fraction, chronic kidney disease, and renal anemia. The seven-month HIF-PH inhibitor daprodustat treatment improved the hemoglobin level from 7.4 g/dL to 11.8 g/dL and estimated glomerular filtration ratio from 24 mL/min/1.73 m
Identifiants
pubmed: 34940544
pii: jcdd8120189
doi: 10.3390/jcdd8120189
pmc: PMC8704914
pii:
doi:
Types de publication
Case Reports
Langues
eng
Références
Eur J Heart Fail. 2002 Dec;4(6):681-6
pubmed: 12453537
Clin J Am Soc Nephrol. 2020 Aug 7;15(8):1155-1165
pubmed: 32723804
Am J Kidney Dis. 2017 Jun;69(6):815-826
pubmed: 28242135
N Engl J Med. 2013 Mar 28;368(13):1210-9
pubmed: 23473338
Curr Med Chem. 2012;19(21):3502-7
pubmed: 22680636
Circulation. 2018 Jul 3;138(1):80-98
pubmed: 29967232
Nephron. 1997;77(2):176-85
pubmed: 9346384
Semin Nephrol. 2006 Jul;26(4):261-8
pubmed: 16949463
N Engl J Med. 2009 Nov 19;361(21):2019-32
pubmed: 19880844